ImpediMed Director Parmjot Bains Steps Down, Retains Significant Equity Interests

The latest update is out from Impedimed Limited ( (AU:IPD) ).

ImpediMed Limited has announced that Dr Parmjot Bains has ceased to be a director of the company as of 7 April 2026, with the notice lodged under ASX listing rule requirements. At the time of cessation, Dr Bains held 21,673 ordinary shares, 8.5 million performance rights, and 8.5 million options in ImpediMed, indicating a substantial equity-linked exposure that may now be relevant for investors monitoring board composition and insider holdings.

The company also confirmed that Dr Bains had no additional indirect interests in ImpediMed securities and no interests in any related contracts at the time of departure. The change marks a shift in the company’s board structure, and stakeholders may assess how this adjustment in governance and aligned incentives could influence future strategic decisions and oversight within the medical technology business.

The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.

More about Impedimed Limited

ImpediMed Limited is an Australian medical technology company focused on bioimpedance-based devices used to measure and monitor body fluid status. Its products are typically aimed at clinical applications, including the management of conditions such as lymphedema and heart failure, serving hospitals and specialist healthcare providers in domestic and international markets.

Average Trading Volume: 6,523,018

Technical Sentiment Signal: Sell

Current Market Cap: A$31.6M

For an in-depth examination of IPD stock, go to TipRanks’ Overview page.